Latest Headlines

Latest Headlines

Dendreon upbeat on ability to make Provenge next year

Dendreon expects to reach full manufacturing capacity for experimental prostate cancer drug Provenge by mid-2011, and will immediately launch sales of the drug when it is approved by U.S. regulators,

Dendreon stays focused on launch countdown

Dendreon may not have an approval yet for its prostate cancer therapy, but it's acting a lot like it's a done deal. In the last two days, Dendreon has raised $356 million from a stock sale and hired

Dendreon files Provenge BLA

Earlier this week, Dendreon completed its revised BLA for Provenge, taking another big step along the road to marketing a new prostate cancer therapy. Dendreon beat its own timetable and hopes to

Dendreon files BLA for Provenge

Seattle-based Dendreon (DNDN) has filed for FDA approval of the prostate cancer drug Provenge, taking another big step as it builds the framework for a national distribution system for the new

Dendreon jumps on 'heavyweight' board appointments

Few vaccine companies get a big bump in their stock prices when they add members to their boards. But you don't often get "heavyweight gunslingers" like these. Dendreon, which is nearing an NDA for

Dendreon blueprints $70M Provenge facility in Atlanta

Seattle-based Dendreon has yet to get FDA marketing approval for Provenge, a next-gen therapeutic cancer vaccine, but the company has confidently blueprinted plans to build a $70 million

Dendreon scouting Atlanta for major manufacturing complex

With an NDA looming for its closely watched prostate cancer drug Provenge, Seattle-based Dendreon is scouting sites in Atlanta for an advanced, $80 million manufacturing site that could employ more

Dendreon CEO predicts an FDA approval for cancer vax

Dendreon CEO Mitchell Gold has had two years to study the FDA's rejection of Provenge back in 2007. Over that period Dendreon has patiently pieced together a positive set of new data supporting the

Is Dendreon a likely takeover target?

The stock analysts like everything they've seen about Dendreon's new data on the prostate cancer vaccine Provenge. They like it so much, some think the biotech has made itself an appealing buyout

Dendreon shares bounce on late-stage Provenge data

Shares of Dendreon went on a wild roller coaster ride yesterday, first plunging dramatically and then soaring back up after the company released new data demonstrating that its prostate cancer